Saroglitazar Mg, approved by the DCGI, is an innovative drug from Zydus to treat chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato Hepatitis (NASH).
Lupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by India s DCGI for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS.
Get latest articles and stories on Latest News at LatestLY. Drug firm Lupin on Friday said it has inked a pact to acquire five drug brands from Italian firm Menarini for Rs 101 crore. Latest News | Lupin Inks Pact to Acquire 5 Drug Brands from Menarini for Rs 101 Crore.
Lupin said it has inked a pact to acquire five drug brands from Italian firm Menarini for Rs 101 crore. The company has signed an agreement to acquire five legacy brands catering to gastroenterology, urology and anti-infective segments, the Mumbai-based company said in a statement.
Lupin s Nagpur facility has received two observations from the USFDA through Form-483 due to violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company assured that it would resolve the issues raised and is confident of doing so soon. The USFDA conducted an inspection of the facility from July 3-11, 2023.